2020年12月20日 · We judiciously functionalised the outer layer of the nanomaterial with N6L, which corresponds to a synthetic agent that is non-toxic to normal mammalian cells, targets surface nucleolin and induces tumour cell death by apoptosis.

siRNA 诱导的 N6L 和核仁素功能丧失通过阻止 PDAC 细胞中的 β-连环蛋白稳定来抑制 Wnt 通路的激活。 N6L 还在小鼠体内和源自 MIA PaCa2 肿瘤的 3D 培养物中抑制了 Wnt/β-catenin 通路的生长和激活。

Our results show that the multivalent pseudopeptide N6L inhibited Matrigel invasion of MDA-MB-435 cells in a modified Boyden chamber model. This was associated with an increase in TIMP-3 in the cell culture medium without a change in TIMP-3 mRNA expression suggesting its release from cell surface and/or extracellular matrix.

3 天之前 · In the present study, we examined the efficacy of N6L in combination with chemotherapy molecules commonly used against human PDAC cells including FOLFOX (5-fluorouracil and oxaliplatin), gemcitabine (GEM) and PTX. We analyzed the synergistic or antagonist effect of each chemotherapeutic molecule in presence of various doses of N6L.

2021年10月1日 · We previously showed that N6L, a pseudopeptide that targets nucleolin, impairs pancreatic ductal adenocarcinoma (PDAC) growth and normalizes tumor vessels in animal models. In this study, we analyzed the translatome of PDAC cells treated with N6L to identify the pathways that were either repressed o …

2018年1月1日 · Recent studies indicated that the N6L multivalent pseudopeptide, a synthetic ligand of cell–surface nucleolin, is also able to bind NPM1 with high affinity. N6L inhibits cell growth with different mechanisms and represents a good candidate as a novel anticancer drug for a number of malignancies of different histological origin.

N6L specifically targets cancer cells, exhibiting anti-tumor activity in various human tumor cell lines derived from mammary, colorectal carcinoma, melanoma and glioblastoma (GB) [12].

核仁素拮抗剂n6l 治疗胰腺导管腺癌，可以促进肿 瘤细胞的凋亡 [3] ；使用抗核仁素的免疫剂4LB5-HP- RNase 治疗乳腺癌，同样发现是通过诱导细胞凋亡

Protein bands showed an increasing intensity from 5 μM to 10 μM in biotinylated-N6L pull-down samples, supporting a dose-dependent efficacy of the interaction with N6L ( Figure S1). ... View in...

多种来源的核仁素的配体、拮抗剂，例如 AS1411、F3 肽和多价伪肽 N6L 已被开发和研究作为癌症的治疗工具。 在过去十年左右的时间里，已经发表的大量研究表明，这些拮抗剂可以与来自不同来源的纳米颗粒一起用作肿瘤靶向剂。 本文重点关注核仁素配体，旨在回顾最近发表的或我们研究团队正在实验的文献，以评估这些工具作为抗肿瘤药物的功效和未来发展。